Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
Myovant Sciences (NYSE: MYOV) announced that David Marek, CEO, will present at the virtual 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myovant Sciences (NYSE: MYOV) announced that David Marek, CEO, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 2:50 p.m. PT. A live webcast will be accessible on Myovant's website under the Investors & Media section.
Myovant focuses on redefining care for women and men, with its lead product candidate, relugolix, approved for advanced prostate cancer. The combination tablet for uterine fibroids is under regulatory review in Europe and the U.S., while MVT-602 is developed for female infertility.
Details
News Market Reaction – MYOV
The recorded move for MYOV in the trading session of this news was -3.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. Pacific Time.
A live webcast of the presentation will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.
About Myovant Sciences
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix (120 mg) is FDA-approved as ORGOVYX™ for adult patients with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.
Investor Contact:
Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
+1 (650) 781-9106
investors@myovant.com
Media Contact:
Albert Liao
Director, Corporate Communications
Myovant Sciences, Inc.
+1 (650) 410-3055
media@myovant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.